Vaxcyte (FRA:5VA) Change In Payables And Accrued Expense : €-0.01 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte Change In Payables And Accrued Expense?

Vaxcyte's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was €-23.56 Mil. It means Vaxcyte's Accounts Payable & Accrued Expense declined by €23.56 Mil from Dec. 2024 to Mar. 2025 .

Vaxcyte's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was €-22.93 Mil. It means Vaxcyte's Accounts Payable & Accrued Expense declined by €22.93 Mil from Dec. 2023 to Dec. 2024 .

Vaxcyte Change In Payables And Accrued Expense Historical Data

The historical data trend for Vaxcyte's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte Change In Payables And Accrued Expense Chart

Vaxcyte Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

29.22

-14.52

13.12

84.38

-22.93

Vaxcyte Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-46.48	-9.63	34.04	-0.86	-23.56

Vaxcyte Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.01 Mil.

Vaxcyte Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Vaxcyte's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxcyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (FRA:5VA) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

PCVX:USA 5VA:Germany

Address

825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070

Website

https://www.vaxcyte.com

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Vaxcyte Headlines

No Headlines